Implant Sales Plump Up Mentor
Sales of Mentor's (MNT) silicone MemoryGel implants provided a lift to the company's fiscal first-quarter results and shares Tuesday.
Excluding the results of discontinued operations of the company's urology business, Mentor reported earning 48 cents a diluted share in the first quarter of fiscal 2008, compared to 33 cents a share in the prior-year quarter -- a 45% increase.
Analysts polled by Thomson Financial had expected 34 cents a share on revenue of $88.4 million.
Net sales rose 20% to $95.6 million compared to $79.4 million in the year-ago quarter. Mentor said the boost in net sales was primarily due to strong sales of its MemoryGel breast implants in the U.S. augmentation market, which Mentor said is transitioning from saline-filled breast implants to silicone breast implants.After the close of the quarter, the company announced it was purchasing all of the outstanding shares of Perouse Plastie SAS, a French breast implant company, for about $56.5 million. "From a strategic standpoint, the acquisition of Perouse Plastie at the end of the quarter expands the company's international product offerings and positions Mentor for future growth and expansion in key international markets," said CEO Joshua Levine. Looking ahead, with that acquisition accounted for, the company expects fiscal 2008 sales to range from $370 million to $385 million for the year and operating income to be about 20% of sales. It expects to earn $1.40 to $1.45 a diluted share from continuing operations. In reaction to the strong quarterly results, Piper Jaffray upgraded Mentor's stock rating from underperform to market perform with a $45 price target. Mentor gained $5.76, or 14.5%, to $46.75 in recent trading Tuesday.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV